Nathalie Trépo
Contacto de Relaciones con Inversores en SparingVision SAS .
Perfil
Nathalie Trépo is currently the Director-Investor Relations & Communications at SparingVision SAS since 2022.
Prior to this, she worked as the Head-Investor Relations at Theradiag SA and Neovacs SA.
Cargos activos de Nathalie Trépo
| Empresas | Cargo | Inicio |
|---|---|---|
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Contacto de Relaciones con Inversores | 01/02/2022 |
Antiguos cargos conocidos de Nathalie Trépo.
| Empresas | Cargo | Fin |
|---|---|---|
| THERADIAG | Contacto de Relaciones con Inversores | - |
| NEOVACS | Contacto de Relaciones con Inversores | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| NEOVACS | Health Technology |
| Empresas privadas | 2 |
|---|---|
Theradiag SA
 Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Health Technology |
- Bolsa de valores
- Insiders
- Nathalie Trépo
